European Commission approves Sobi’s Aspaveli for the treatment of C3G and primary IC-MPGN: Stockholm Monday, January 19, 2026, 10:00 Hrs [IST] Sobi, a global biopharma company u ...

Background Both host and microbe metabolism of tryptophan (Trp) is altered in diabetes; however, the molecular mechanisms are ...

Sweden’s Sobi has announced that the European Commission (EC) has approved Aspaveli (pegcetacoplan) for adults and ...

It doesn’t take a rocket ― er, dick scientist ― to know that it’s not just whiskey that causes whiskey dick. Vodka drinkers ...

Blood pressure medicines are among the most commonly prescribed drugs in the world. Millions of people take them every day to ...

Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of ...

SaveHealth reports on 10 hypertension medications, their classifications, effectiveness, side effects, and safety in managing high blood pressure.

Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 ...

Exposure to extreme cold conditions coupled with pollution increases the risk of preterm births and a rise in blood pressure ...

IgA nephropathy is a type of kidney disease that is typically treated with various medicines and lifestyle changes. Learn more about IgA nephropathy treatment here.

India are taking on New Zealand at the Niranjan Shah Stadium in Rajkot in the second ODI of the three-match series.